Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease

Journal of the American Society of Nephrology

Volumn 22, Issue 8, 2011, Pages 1486-1496

  Iyoda, Masayuki ^a   Shibata, Takanori ^a   Hirai, Yuki ^a   Kuno, Yoshihiro ^a   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NILOTINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIDNEY INJURY; LAPAROTOMY; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SURVIVAL RATE;

EID: 79960952805     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010111158     Document Type: Article

References (48)

1. Buchdunger E, O'Reilly T, Wood J: Pharmacology of imatinib (STI571). Eur J Cancer 38[Suppl 5]: S28-S36, 2002
2. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324-1332, 2001 (Pubitemid 32281220)
3. Savikko J, Taskinen E, Von Willebrand E: Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: Tyrosine kinase inhibitors as a potential therapy. Transplantation 75: 1147-1153, 2003 (Pubitemid 36513012)
4. Lassila M, Jandeleit-Dahm K, Seah KK, Smith CM, Calkin AC, Allen TJ, Cooper ME: Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16: 363-373, 2005 (Pubitemid 41725131)
5. Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G: Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70: 97-103, 2006 (Pubitemid 44000125)
6. Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M: Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 52: 3987-3996, 2005 (Pubitemid 41798238)
7. Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19: 1-11, 2005 (Pubitemid 40069914)
8. Iyoda M, Hudkins KL, Becker-Herman S, Wietecha TA, Banas MC, Guo S, Meyer-Bahlburg A, Kowalewska J, Liu G, Ziegler SF, Rawlings DJ, Alpers CE: Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol 20: 68-77, 2009
9. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with antiglomerular basement membrane glomerulonephritis. Kidney Int 75: 1060-1070, 2009
10. Manley PW, Cowan-Jacob SW, Mestan J: Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 1754: 3-13, 2005 (Pubitemid 41797682)
11. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 94: 1765-1769, 2006 (Pubitemid 43882564)
12. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG: The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106: 3206-3213, 2005 (Pubitemid 41565920)
13. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher, N: Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18: 6977-6986, 2010
14. Shaker ME, Salem HA, Shiha GE, Ibrahim, TM: Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam Clin Pharmacol 25: 248-257, 2011
15. Riser BL, Varani J, Cortes P, Yee J, Dame M, Sharba AK: Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: A possible new mechanism for glomerulosclerosis. Am J Pathol 158: 11-17, 2001 (Pubitemid 32096465)
16. Floege J, Alpers CE, Burns MW, Pritzl P, Gordon K, Couser WG, Johnson RJ: Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 66: 485-497, 1992
17. Fujihara CK, Malheiros DM, Zatz R, Noronha IL: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 54: 1510-1519, 1998 (Pubitemid 28502893)
18. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY: Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 13: 1967-1974, 1998 (Pubitemid 28356760)
19. Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 41: 297-309, 1992
20. Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49: 666-678, 1996 (Pubitemid 26093075)
21. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE: Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 44: 195-202, 2004 (Pubitemid 39014239)
22. Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM: Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47: 467-474, 2006 (Pubitemid 43740292)
23. Linseman DA, Benjamin CW, Jones DA: Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 270: 12563-12568, 1995
24. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T: Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen- activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273: 8890-8896, 1998 (Pubitemid 28176171)
25. Escano CS Jr, Keever LB, Gutweiler AA, Andresen BT: Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: Implications for blood pressure regulation. J Pharmacol Exp Ther 324: 34-42, 2008 (Pubitemid 350294145)
26. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S: Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099, 2004 (Pubitemid 39038030)
27. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F: Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 18: 1332-1339, 2004 (Pubitemid 39136740)
28. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105: 2473-2479, 2005 (Pubitemid 40387048)
29. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH: Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116: 2633-2642, 2006 (Pubitemid 44511627)
30. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB: Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105: 3127-3132, 2005
31. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB: Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 17: 1713-1721, 2003 (Pubitemid 37185245)
32. Gu JJ, Zhang N, He YW, Koleske AJ, Pendergast AM: Defective T cell development and function in the absence of Abelson kinases. J Immunol, 179: 7334-7343, 2007
33. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crepineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mecheri S, Tursz T, Zitvogel L: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388, 2004 (Pubitemid 39071610)
34. Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II. Kidney Int Suppl 63: S221-S225, 1997 (Pubitemid 28020477)
35. Schiller B, Moran J: Focal glomerulosclerosis in the remnant kidney model-An inflammatory disease mediated by cytokines. Nephrol Dial Transplant 12: 430-437, 1997 (Pubitemid 27105614)
36. Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson DW: Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-beta-dependent mechanism. J Lab Clin Med 140: 342-350, 2002 (Pubitemid 35302027)
37. Vesey DA, Cheung CW, Cuttle L, Endre ZA, Gobe G, Johnson DW: Interleukin-1beta induces human proximal tubule cell injury, alphasmooth muscle actin expression and fibronectin production. Kidney Int 62: 31-40, 2002 (Pubitemid 34754045)
38. Lonnemann G, Engler-Blum G, Muller GA, Koch KM, Dinarello CA: Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. Kidney Int 47: 845-854, 1995
39. Lonnemann G, Shapiro L, Engler-Blum G, Muller GA, Koch KM, Dinarello CA: Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int 47: 837-844, 1995
40. Ota T, Tamura M, Osajima A, Doi Y, Kudo H, Anai H, Miyazaki M, Nishino T, Nakashima Y: Expression of monocyte chemoattractant protein-1 in proximal tubular epithelial cells in a rat model of progressive kidney failure. J Lab Clin Med 140: 43-51, 2002 (Pubitemid 34703346)
41. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee KW, Ziai F, Jiang T, Brenner BM, MacKenzie HS: Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int 58: 1664-1676, 2000
42. Jones LK, O'Sullivan KM, Semple T, Kuligowski MP, Fukami K, Ma FY, Nikolic-Paterson DJ, Holdsworth SR, Kitching AR: IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol Dial Transplant 24: 3024-3032, 2009
43. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, Kuziel WA, Matsushima K, Mukaida N, Yokoyama H: Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 165: 237-246, 2004 (Pubitemid 38821831)
44. Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, Hashimoto H, Ishiwata Y, Mukaida N, Tomosugi N, Matsushima K, Egashira K, Yokoyama H: Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 15: 940-948, 2004 (Pubitemid 38375313)
45. Wang S, Wilkes MC, Leof EB, Hirschberg, R: Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142-F149, 2010
46. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002 (Pubitemid 34760789)
47. Kivirikko KI, Laitinen O, Prockop DJ: Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 19: 249-255, 1967
48. Gallop PM, Paz MA: Posttranslational protein modifications, with special attention to collagen and elastin. Physiol Rev 55: 418-487, 1975